Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ibrexafungerp citrate by GSK for Systemic Candidiasis: Likelihood of Approval
Ibrexafungerp citrate is under clinical development by GSK and currently in Phase III for Systemic Candidiasis. According to GlobalData, Phase...
Ibrexafungerp citrate by GSK for Blastomycosis: Likelihood of Approval
Ibrexafungerp citrate is under clinical development by GSK and currently in Phase III for Blastomycosis. According to GlobalData, Phase III...
Ibrexafungerp citrate by GSK for Histoplasmosis: Likelihood of Approval
Ibrexafungerp citrate is under clinical development by GSK and currently in Phase III for Histoplasmosis. According to GlobalData, Phase III...
Ibrexafungerp citrate by GSK for Candidiasis: Likelihood of Approval
Ibrexafungerp citrate is under clinical development by GSK and currently in Phase III for Candidiasis. According to GlobalData, Phase III...
Ibrexafungerp citrate by GSK for Aspergillosis: Likelihood of Approval
Ibrexafungerp citrate is under clinical development by GSK and currently in Phase III for Aspergillosis. According to GlobalData, Phase III...
Ibrexafungerp citrate by GSK for Coccidioidomycosis: Likelihood of Approval
Ibrexafungerp citrate is under clinical development by GSK and currently in Phase III for Coccidioidomycosis. According to GlobalData, Phase III...
Ibrexafungerp citrate by GSK for Fungal Infections: Likelihood of Approval
Ibrexafungerp citrate is under clinical development by GSK and currently in Phase III for Fungal Infections. According to GlobalData, Phase...